IRFMNi001-B-2

CIone M CIITAKO-B2MKO

General

Cell Line

hPSCreg name IRFMNi001-B-2
Cite as:
IRFMNi001-B-2 (RRID:CVCL_C1TS)
Alternative name(s)
CIone M CIITAKO-B2MKO
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
IRFMNi001-B-1
(Clone XI CIITAKO)
IRFMNi001-B
(iPS clone XI)
DHMi005-A-8
(L Delta B2M Clone 6)
DHMi005-A-9
(L Delta B2M Clone 11)
RCPCMi007-A-1
(IPSFF1S deltab2m)
MUSIi001-A-1
(B2M-KO-SFiPSC5)
CHAHESe001-A-1
(CHA-hES NT6 B2M KO#67)
Donor diseases:
age-related macular degeneration
IRFMNi001-A
(iPS clone IV)
Last update 5th August 2022
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator IRCCS - Istituto di Ricerche Farmacologiche Mario Negri (IRFMN)
Derivation country Italy

External Databases

BioSamples SAMEA110465773
Cellosaurus CVCL_C1TS
Wikidata Q114311766

General Information

Publications
* Is the cell line readily obtainable for third parties?
No
Subclone of

Donor Information

General Donor Information

Sex male
Ethnicity caucasian

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA104008499

Ethics

Also have a look at the ethics information for the parental line IRFMNi001-B .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

The source cell information can be found in the parental cell line IRFMNi001-B.

Reprogramming method

Vector type None

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzymatically
Medium mTeSR™ Plus
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
NANOG
Yes
SOX2
Yes
SSEA-3
Yes
SSEA-4
Yes
TRA 1-60
Yes
TRA 1-81
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
alpha fetoprotein
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
smooth muscle actin
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
tubulin beta 3 class III
Yes

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification

Genetic modifications not related to a disease
CIITA – class II major histocompatibility complex transactivator (target)
Gene knock-out
16p13.13
CRISPR-associated (CRISPR/Cas) System
B2M beta-2-microglobulin (target)
Gene knock-out
15q21.1
CRISPR-associated (CRISPR/Cas) System